Skip to main content

Table 3 Selected studies presentation for venlafaxine

From: Duloxetine compared with fluoxetine and venlafaxine: use of meta-regression analysis for indirect comparisons

Study Inclusion criteria Age Percent male duration (weeks) Treatment Dosage (mg/day) Patients per arm Effect size (SD) Response (%) Dropouts (%)
Khan et al. [36] DSM-III, HAMD-D ≥ 20 41
41
41
0.44
0.44
0.44
6 Venlafaxine
Venlafaxine
Venlafaxine
Placebo
75
75–225
150–375
23
22
22
26
-0.8(0.1)
-0.6(0.1)
-0.7(0.1)
  0.21
0.15
Schweizer et al. [37] DSM-III-R, Age 24–63
HAMD-D ≥ 20
46
46
46
0.60
0.60
0.60
6 Venlafaxine
Venlafaxine
Venlafaxine
Placebo
75
225
375
15
15
14
16
-0.6(0.1)
-1.2(0.2)
-1.1(0.2)
  0.43
0.57
Cunningham et al. [38] DSM-III-R, Age ≥ 18
HAMD-D ≥ 20
41 0.33 6 Venlafaxine
Trazodone
Placebo
25–200
50–400
72
77
76
-0.4(0.03) 0.72
0.55
0.29
0.36
Schweizer et al. [39] DSM-III-R, Age≥ 18
HAMD-D21 ≥ 20
41 0.31 6 Imipramine
Venlafaxine
Placebo
75–225
75–225
73
73
78
-0.6(0.03) 0.77
0.47
0.36
0.27
Cunningham et al. [40] DSM-III-R, Age ≥ 18
HAMD-D ≥ 20
40
43
0.38
0.39
12 Venlafaxine XR
Venlafaxine IR
Placebo
75–150
75–150
97
96
100
-0.5(0.02)
-0.5(0.02)
0.68
0.52
0.31
0.29
0.40
0.41
Thase et al. [41] DSM-IV, Age ≥ 18
HAMD-D21 ≥ 20
40 0.39 8 Venlafaxine XR
Placebo
75–225 91
100
-0.6(0.02) 0.58
0.29
0.27
0.40
Rudolph et al. [34] DSM-IV, Age ≥ 18
HAMD-D21 ≥ 20
40 0.32 8 Fluoxetine
Venlafaxine XR
Placebo
20–60
75–225
103
100
98
-0.1(0.02) 0.57
0.42
0.19
0.21
Silverstone et al. [42] DSM-IV, Age ≥ 18
HAMD-D21 ≥ 20 (on the first 17 items), Covi ≥ 8
41 0.39 12 Fluoxetine
Venlafaxine XR
Placebo
20–60
75–225
121
128
119
-0.4(0.02) 0.67
0.43
0.29
0.40
Globally NA 42 ± 2 0.43 8 ± 3 Venlafaxine
Placebo
75–225 768
613
-0.51(0.07) 1.28(0.26) ** -0.25(0.12) **
  1. ** Log Odds ratios (SD)